CAPR - Capricor Therapeutics, Inc.
| Previous Close | 1.4200 |
| Open | 1.3900 |
| Bid | 1.2500 x 1100 |
| Ask | 1.2800 x 1100 |
| Day's Range | 1.2100 - 1.3900 |
| 52 Week Range | 0.8800 - 8.8500 |
| Volume | 1,168,711 |
| Avg. Volume | 591,854 |
| Market Cap | 6.743M |
| Beta (5Y Monthly) | 2.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0590 |
| Earnings Date | May 10, 2020 - May 14, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
- GlobeNewswire
Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced that it will host a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on Thursday, March 26, 2020 at 12pm Eastern Time. The call will feature a presentation by KOL and newly appointed Capricor Executive Consultant Stephen J. Gould, Ph.D., from Johns Hopkins University, who will provide an overview of an exosome-based vaccine approach. Capricor is committed to developing precision-engineered exosomes that carry defined sets of effector molecules which exert their effects through defined mechanisms of action.
- Zacks
4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis
Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.
- GlobeNewswire
Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
-To Report Final 12-month HOPE-2 Data in the Second Quarter- -Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus- -To Host Conference Call and.
- ACCESSWIRE
Capricor Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Capricor Therapeutics, Inc. (NASDAQ:CAPR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 18, 2020 ...
- GlobeNewswire
Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion
Capricor Therapeutics (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced the expansion of its strategic plan to further develop the company’s exosome platform technologies. In conjunction with these efforts, Stephen Gould, Ph.D. has been appointed as Executive Consultant to guide Capricor’s development of exosome-based vaccines and exosome-based therapeutics.
- GlobeNewswire
Capricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18
Capricor Therapeutics (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders will release its financial results for the fourth quarter and full year ended December 31, 2019, shortly after the NASDAQ market close on Wednesday, March 18. Management will then host a webcast and conference call at 4:30 p.m. ET on March 18.
- Simply Wall St.
Does Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay Reflect Performance?
Linda Marbán became the CEO of Capricor Therapeutics, Inc. (NASDAQ:CAPR) in 2010. First, this article will compare CEO...
- Zacks
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?
Is (CAPR) Outperforming Other Medical Stocks This Year?
- Zacks
Top Ranked Momentum Stocks to Buy for February 3rd
Top Ranked Momentum Stocks to Buy for February 3rd
- Zacks
Top Ranked Momentum Stocks to Buy for January 28th
Top Ranked Momentum Stocks to Buy for January 28th
- GlobeNewswire
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
Capricor Therapeutics, Inc. (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced the closing of the previously announced offering priced at-the-market of 4,139,477 shares of the Company’s common stock (or common stock equivalents), at a purchase price of $1.226 per share and associated warrant. Each share of common stock (or common stock equivalent) offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.10 per share and a five-year term. The gross proceeds to Capricor, before deducting placement agent fees and other offering expenses, are approximately $5.1 million.
- GlobeNewswire
Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market
Capricor Therapeutics, Inc. (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced that it has entered into a definitive securities purchase agreement with a single, healthcare-dedicated institutional investor for the purchase in an offering priced at-the-market of 4,078,304 shares of the Company’s common stock (or common stock equivalents), at a purchase price of $1.226 per share and associated warrant. In addition, select members of the Company's Board of Directors are participating in the offering. Each share of common stock (or common stock equivalent) offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.10 per share and a five-year term.
- Simply Wall St.
We're A Little Worried About Capricor Therapeutics's (NASDAQ:CAPR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- Zacks
Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates
Capricor (CAPR) delivered earnings and revenue surprises of 38.57% and -35.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
Provides Update on End of Phase Type-B Meeting with FDA Positive Data from the HOPE-2 Clinical Trial Presented at World Muscle Society To Host Conference Call and.
- GlobeNewswire
Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7
Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its third quarter of 2019 financial results and corporate update shortly after the NASDAQ market close on Thursday, November 7. Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of DMD.
- Simply Wall St.
How Capricor Therapeutics, Inc. (NASDAQ:CAPR) Can Impact Your Portfolio Volatility
If you're interested in Capricor Therapeutics, Inc. (NASDAQ:CAPR), then you might want to consider its beta (a measure...
- GlobeNewswire
Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced today that it will host a Key Opinion Leader (KOL) call on the role of CAP-1002 in the of treatment of Duchenne Muscular Dystrophy (DMD) on Thursday, October 24th at 10:30am Eastern Time. The call will feature a presentation by KOL Craig M. McDonald, MD, UC Davis Health, and principal investigator of Capricor’s HOPE-2 trial who will provide an overview of Duchenne Muscular Dystrophy (DMD), its progression, current treatment options, and new treatments in development for the disease.
- Zacks
CHF Solutions System to be Used in JAHVH Study After Final Nod
CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For October 7, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Roku (NASDAQ: ROKU ) shares were down 0.8% ...
- GlobeNewswire
Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months
Capricor Therapeutics, Inc. (CAPR), a clinical-stage biotechnology company, in its presentation at the 24th Annual International Congress of the World Muscle Society, presented additional six-month interim data from HOPE-2, its ongoing Phase 2 clinical trial of its lead investigational product, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 is Capricor’s cell-based therapeutic candidate whose mechanism of action is immunomodulatory, anti-fibrotic and has been shown to generate new muscle cells. Data from the pre-specified interim analysis demonstrated that teens and young men in the advanced stages of DMD saw improvements in skeletal, pulmonary, and cardiac measurements after receiving multiple doses of CAP-1002.
- Zacks
Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock?
Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.
- GlobeNewswire
Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET
Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced that it will present interim results from the randomized, double-blind, Phase II HOPE-2 clinical trial of CAP-1002 in boys and young men with Duchenne muscular dystrophy (DMD) at the 24th International Congress of the World Muscle Society. Dr. Craig McDonald, a professor of pediatrics, professor and chair of the Department of Physical Medicine and Rehabilitation, director of Rehabilitation Services, director of the Neuromuscular Disease Clinics at UC Davis Health and national principal investigator for the HOPE-2 study will present the results.
- Zacks
Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System
Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.
- Zacks
Align Gains on Innovation Despite Poor Case Shipment in China
Align Technology (ALGN) succeeds in consecutively delivering a solid spurt in Invisalign Technology volumes across the company's entire clientele.
